|
|
|
1,001-5,000 employees
View all
|
|
biotechnology
|
|
55 Cambridge Parkway,Cambridge,MA,US
|
|
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.See our community guidelines: bit.ly/39o3O6j
|
BeiGene Email Formats | Example Email Formats | Percentage |
---|---|---|
{first}.{last} | [email protected] |
87.5%
|
The widely used BeiGene email format is {first}.{last} (e.g. [email protected]) with 87.5% adoption across the company.
To contact BeiGene customer service number in your country click here to find.
John Oyler is the CEO of BeiGene. To contact John Oyler email at [email protected], [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.